Imugene Limited

Imugene (ASX:IMU) is an immuno-oncology focused biopharmaceutical company developing HER-2+ gastric and breast cancer immunotherapies. Our mission is to build a pipeline of B-cell peptide cancer vaccines.

Email Alerts for:
ASX:IMU

Latest Media Releases

Quarterly Activities and Cash Flow Report Quarter ended 31 December 2019

Key Highlights: Imugene completes oversubscribed placement of $24.6 million to fund clinical programs on 02- December, 2019 Professor Yuman Fong appointed Chairman of the Oncolytic Virotherapy S…

Imugene PD1-Vaxx Immunotherapy Update

Sydney, Australia, 28 January 2020: Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company today announces a clinical development update on its PD1-Vaxx cancer immunotherapy. PD1- Vaxx w…

Imugene HER-Vaxx Immunotherapy Patent Granted in United States

Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company today announced it has received a Notice of Grant from the United States Patent and Trademark Office (USPTO) for Patent Application…

Latest News

Recession fears trigger equities rout, leaving retailers in the dust: ASX closes 1.7% lower

19 May 2022 - More pain for investors as a wave of selling on recession and inflation fears exacerbated by profit misses from retail giants Target and Walmart hit US markets, with …

Jobless rate to 3.9%, Aristocrat jumps as retailers tumble, inflation haunts: ASX dives 1.5% at noon

19 May 2022 - Consumer staples and discretionary stocks are leading the dive on the Australian sharemarket, shrugging off the improved labour market, giving back 3 days of gains.

China's economy slumps in April: ASX closes 0.3% higher

16 May 2022 - Australian shares struggled to maintain their early morning rally after China revealed that it had suffered an 11.1 per cent drop in retail sales during April, which …

Pendal pops on 1H profit beat: ASX falls for 3rd straight day, tumbling 1.3% at noon

10 May 2022 - Resources stocks are pulling the index lower for a third straight day as investors continue to sell out stocks on concerns around the impact of rising interest rates …

Tech leads ASX tumble, Travel stocks lift: Aus shares close 1.2% lower

02 May 2022 - The ASX had a rough session today ahead of the interest rate outcome tomorrow from the Reserve Bank of Australia. Meanwhile, a weak lead from Wall Street sent Aussie …

Tech shares tumble while energy leads: ASX closes 0.8% lower

27 Apr 2022 - Australian inflation came in hotter-than-expected today, with trimmed mean well above the RBA's 2% to 3% target band and firming bets the central bank will begin lift…

S&P 500 gains 8% in 2-weeks, best run since 2020, Rio, FMG, Macquarie, Scentre on watch: ASX to rise

28 Mar 2022 - Global markets closed mixed on Friday, rising US treasury bond yields boosted financials though hurt growth stocks while rising commodity prices limited losses. An at…

Imugene (ASX:IMU) receives approval to commence US clinical trial

23 Mar 2022 - Imugene (ASX:IMU) has received approval from the western institutional review board to commence a phase 1 clinical trial of its oncolytic virotherapy candidate, VAXIN…

Block leads tech's surge, Fisher & Paykel tumbles on revenue guidance: ASX up 0.5% at noon

23 Mar 2022 - Following Wall St’s lead, the ASX opened higher and has stayed in positive territory as technology takes the crown from materials. The local bourse continues to be vo…

Mining rout prompts a rethink on China's lockdown: ASX down 0.6% at noon

15 Mar 2022 - The banking bulls’ resilient rally amid a surge in treasury yields has taken the spotlight on the ASX, ahead of two central banks to unveil its interest rate decision…

Healthcare leads, Miners & energy fall: ASX closes 0.8% lower

08 Mar 2022 - After see-saw trading this morning, the ASX fell into negative territory in the afternoon session as investors searched for safety amid the US and allies mulling a ba…

ASX rallies, Imugene jumps 10%: ASX down 2.7% over the week

28 Jan 2022 - The ASX rallied in the afternoon, finishing Friday’s session on a positive note after a plummeting week. All sectors closed higher with consumer staples and consumer …

Imugene (ASX:IMU) reports on two vaccines

28 Jan 2022 - Bio-tech company Imugene (ASX:IMU) has made two announcements today regarding its HER-Vaxx and PD1-Vaxx.

Stocks of the Hour: Imugene, Beach Energy & Woodside Petroleum

16 Nov 2021 - A snapshot of the stocks on the move, featuring Imugene (ASX:IMU), Beach Energy (ASX:BPT), Woodside Petroleum (ASX:WPL).

ASX falls, Miners drag, Mesoblast drops 5%: ASX down 0.5% at noon

16 Nov 2021 - The ASX is dragging lower this morning as miners weigh on the index. At noon, the S&P/ASX 200 is 0.5% or 37.7 points lower at 7432.4. The SPI futures are pointing to …

Imugene (ASX:IMU) to proceed to final dose cohort for lung cancer treatment

07 Apr 2021 - $620 million cancer treatment provider Imugene (ASX:IMU) has announced that an independent team of researchers have certified that lung cancer drug PD1-Vaxx is safe f…

President Trump contracts Covid-19: Aus shares close 1.4% lower

02 Oct 2020 - The Aussie dollar has toppled, and US futures are looking bleak after confirmation that President Donald Trump and First Lady Melania Trump have contracted Covid-19. …

Imugene (ASX:IMU) secures core US patent

02 Oct 2020 - Immuno-oncology company, Imugene (ASX:IMU) has been granted a patent from the US United States Patent and Trademark Office which it says protects its cancer growth fa…

Imugene (ASX:IMU) report PD1-Vaxx generates high levels of antibodies

28 Jan 2020 - Immuno-therapy company Imugene (ASX:IMU) report that studies have shown their PD1-Vaxx cancer immunotherapy drug generates high levels of antibodies.

Lithium shares continue to rally: Aus shares close 0.9% higher

14 Jan 2020 - It’s been a positive day of trade for the Australian share market closing 0.9 per cent higher. Kangaroo Island Plantation Timbers (ASX:KPT) report further damage.

Imugene (ASX:IMU) receives US patent approval for HER-VAxx

14 Jan 2020 - Immuno-therapy company Imugene (ASX:IMU) has received the US patent for its HER-VAxx cancer treatment.

Imugene Limited (ASX:IMU) completes OV acquisition: Aus shares 0.6% lower at noon

18 Nov 2019 - Australian share market dipped on open despite ‘constructive discussions’ regarding the phase-one China and US trade deal between negotiators. Imugene Limited (ASX:IM…

RBA cut rates to historical low, banks under pressure: Aus shares close 0.1% higher

02 Jul 2019 - Australian share market falls after RBA cut rates as expected to 1%, but the ASX200 claws back into positive territory, rising for the 2nd session. Financials lost ov…

Imugene (ASX:IMU) Presentation, FNN Investor Event, May 2019, Sydney

27 May 2019 - Imugene Limited (ASX:IMU) Managing Director & CEO, Leslie Chong presents on trial progress with the company's HER-B Vaxx cancer vaccines, the advantages of B-cell vac…

Imugene (ASX:IMU) targeting gastric cancer

27 May 2019 - Imugene Limited (ASX:IMU) Managing Director & CEO, Leslie Chong discusses trial progress with the company's HER-B Vaxx cancer vaccines, the advantages of B-cell vacci…